Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice

1 juni 2015 uppdaterad av: Boehringer Ingelheim

Observational Study Assessing the Safety, Efficacy and Treatment Adherence of Nevirapine Extended Release (Combined With Other Antiretroviral Drugs) in HIV Infected Patients in Daily Clinical Practice

This Post Marketing Surveillance study will be performed as an open-label, prospective, non-interventional, uncontrolled study in Human immunodeficit Virus-1 (HIV-1) infected patients. Data will only be documented in patients for whom a pharmacotherapy with nevirapine extended release is initiated. Both anti-retroviral therapy (ART) naïve patients and pre-treated patients switching from nevirapine immediate release or other anti-retroviral therapy (ART) will be included in the study. The decision to initiate treatment with nevirapine extended release is independent of this study and is based entirely on individual patient need and the judgement of the treating physician. The aim of the study is to assess the safety and efficacy and treatment adherence of nevirapine extended release in HIV-1 infected patients in routine clinical practice. It is planned to document five visits for each patient over a twenty four week observational period.

Studieöversikt

Status

Avslutad

Betingelser

Detaljerad beskrivning

Study Design:

non-interventional uncontrolled observational study

Studietyp

Observationell

Inskrivning (Faktisk)

398

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

      • Bialystok, Polen
        • Boehringer Ingelheim Investigational Site 8
      • Bialystok, Polen
        • Boehringer Ingelheim Investigational Site 7
      • Bydgoszcz, Polen
        • Boehringer Ingelheim Investigational Site 9
      • Bydgoszcz, Polen
        • Boehringer Ingelheim Investigational Site 10
      • Chorzów, Polen
        • Boehringer Ingelheim Investigational Site 11
      • Chorzów, Polen
        • Boehringer Ingelheim Investigational Site 12
      • Gdañsk, Polen
        • Boehringer Ingelheim Investigational Site 13
      • Gdañsk, Polen
        • Boehringer Ingelheim Investigational Site 14
      • Gdañsk, Polen
        • Boehringer Ingelheim Investigational Site 15
      • Kraków, Polen
        • Boehringer Ingelheim Investigational Site 16
      • Kraków, Polen
        • Boehringer Ingelheim Investigational Site 17
      • Poznañ, Polen
        • Boehringer Ingelheim Investigational Site 18
      • Wroc£aw, Polen
        • Boehringer Ingelheim Investigational Site 19
      • Wroc£aw, Polen
        • Boehringer Ingelheim Investigational Site 20
      • Bacau, Rumänien
        • Boehringer Ingelheim Investigational Site 50
      • Brasov, Rumänien
        • Boehringer Ingelheim Investigational Site 51
      • Brasov, Rumänien
        • Boehringer Ingelheim Investigational Site 52
      • Brasov, Rumänien
        • Boehringer Ingelheim Investigational Site 53
      • Bucuresti, Rumänien
        • Boehringer Ingelheim Investigational Site 21
      • Bucuresti, Rumänien
        • Boehringer Ingelheim Investigational Site 22
      • Bucuresti, Rumänien
        • Boehringer Ingelheim Investigational Site 23
      • Bucuresti, Rumänien
        • Boehringer Ingelheim Investigational Site 24
      • Bucuresti, Rumänien
        • Boehringer Ingelheim Investigational Site 25
      • Bucuresti, Rumänien
        • Boehringer Ingelheim Investigational Site 26
      • Bucuresti, Rumänien
        • Boehringer Ingelheim Investigational Site 27
      • Bucuresti, Rumänien
        • Boehringer Ingelheim Investigational Site 28
      • Bucuresti, Rumänien
        • Boehringer Ingelheim Investigational Site 29
      • Bucuresti, Rumänien
        • Boehringer Ingelheim Investigational Site 30
      • Bucuresti, Rumänien
        • Boehringer Ingelheim Investigational Site 31
      • Bucuresti, Rumänien
        • Boehringer Ingelheim Investigational Site 32
      • Bucuresti, Rumänien
        • Boehringer Ingelheim Investigational Site 33
      • Bucuresti, Rumänien
        • Boehringer Ingelheim Investigational Site 34
      • Bucuresti, Rumänien
        • Boehringer Ingelheim Investigational Site 35
      • Bucuresti, Rumänien
        • Boehringer Ingelheim Investigational Site 36
      • Bucuresti, Rumänien
        • Boehringer Ingelheim Investigational Site 37
      • Bucuresti, Rumänien
        • Boehringer Ingelheim Investigational Site 38
      • Bucuresti, Rumänien
        • Boehringer Ingelheim Investigational Site 39
      • Bucuresti, Rumänien
        • Boehringer Ingelheim Investigational Site 40
      • Bucuresti, Rumänien
        • Boehringer Ingelheim Investigational Site 41
      • Bucuresti, Rumänien
        • Boehringer Ingelheim Investigational Site 42
      • Bucuresti, Rumänien
        • Boehringer Ingelheim Investigational Site 43
      • Bucuresti, Rumänien
        • Boehringer Ingelheim Investigational Site 44
      • Constanta, Rumänien
        • Boehringer Ingelheim Investigational Site 46
      • Constanta, Rumänien
        • Boehringer Ingelheim Investigational Site 47
      • Constanta, Rumänien
        • Boehringer Ingelheim Investigational Site 48
      • Giurgiu, Rumänien
        • Boehringer Ingelheim Investigational Site 45
      • Ploiesti, Rumänien
        • Boehringer Ingelheim Investigational Site 49
      • Graz, Österrike
        • Boehringer Ingelheim Investigational Site 6
      • Salzburg, Österrike
        • Boehringer Ingelheim Investigational Site 5
      • Vienna, Österrike
        • Boehringer Ingelheim Investigational Site 1
      • Vienna, Österrike
        • Boehringer Ingelheim Investigational Site 2
      • Vienna, Österrike
        • Boehringer Ingelheim Investigational Site 3
      • Wels, Österrike
        • Boehringer Ingelheim Investigational Site 4

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 64 år (Vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Testmetod

Sannolikhetsprov

Studera befolkning

HIV-1 infected patients

Beskrivning

Inclusion criteria:

  1. HIV-1 infected male and female 18 years and above;
  2. anti-retroviral therapy (ART) naive and pre-treated patients switching from a nevirapine immediate release or other ART.

Exclusion criteria:

Consistent with the current VIRAMUNE prolonged release SPC.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

Kohorter och interventioner

Grupp / Kohort
nevirapine extended release

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Number of Patients Reporting Non-serious Adverse Events, Serious Adverse Events, and Non-serious and Serious Adverse Events Leading to Treatment Discontinuation
Tidsram: up to 72 weeks
The primary endpoint is to evaluate the safety of a highly active antiretroviral therapy (HAART) that includes nevirapine extended release in routine clinical practice which is to assess the number of patients reporting non-serious adverse events (nSAEs), the number of patients with serious adverse events (SAE), the number of patients with non-serious adverse events leading to treatment discontinuation, and the number of patients with serious adverse events leading to discontinuation.
up to 72 weeks
Number of Patients Reporting Rash of Any Severity
Tidsram: up to 72 weeks
Number of patients reporting rash of any severity as adverse event
up to 72 weeks
Number of Patients Reporting Hepatic Events
Tidsram: up to 72 weeks
Number of patients reporting hepatic events either as adverse event (AE) or as laboratory abnormality of Grade 1 to Grade 4 in aspartate aminotransferase (AST), alanine transaminase (ALT), Gamma-Glutamyl-Transferase (Gamma-GT) and bilirubin.
up to 72 weeks

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Number of Patients With Virologic Response at Week 24 (Viral Load <50 Copies/mL)
Tidsram: 24 weeks
Virologic response is defined as confirmed Human Immunodeficiency Virus (HIV) viral load of < 50 copies/mL (at two consecutive measurements after baseline) up to week 24 and without subsequent rebound or change of anti-retroviral (ARV) therapy up to week 24. A rebound is defined as two consecutive measurements of viral load (VL) ≥ 50 copies/mL, at least two weeks apart, after two consecutive measurements of VL< 50 copies/mL. A change of ARV therapy is defined as a permanent discontinuation of nevirapine extended release, addition of new ARV drugs, or alteration in background therapy. A change in the background therapy due to toxicity or intolerance is not considered as treatment failure. If no follow-up viral load was available the virologic response is Missing.
24 weeks
Change in CD4+ Cell Count From Baseline to Week 24
Tidsram: baseline and week 24
The change in the Cluster of differentiation 4 (CD4+) cell count from baseline after 24 weeks was calculated by subtracting the baseline value from the value after 24 weeks. Therefore, a positive change represents an increase in CD4+ cell count.
baseline and week 24
Change in Morisky Medication Adherence Scale Score From Baseline to 24 Weeks
Tidsram: baseline and week 24
The Morisky Medication Adherence scale (MMAS-8 scale) is a recognized indicator of medication adherence, consisting of 8 questions with a sum score ranging between 0 and 8 points. The higher score indicates higher adherence to the prescribed therapy recommendation. It has been agreed that the score of 8 could be categorized as having high adherence, score between 6 and 7 as medium adherence and scores of 5 and less as low adherence. The change is presented as the score after 24 weeks minus the score at baseline. Therefore, a positive change score reflects an improvement in the adherence.
baseline and week 24
Number of Patients Reporting Once Daily Nevirapine Intake More Convenient Than Twice Daily Formulation
Tidsram: 24 weeks
The number of patients reporting that they find the once daily nevirapine intake more / very much more convenient than the twice daily formulation.
24 weeks

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Användbara länkar

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart

1 mars 2012

Primärt slutförande (Faktisk)

1 maj 2014

Avslutad studie (Faktisk)

1 maj 2014

Studieregistreringsdatum

Först inskickad

17 januari 2012

Först inskickad som uppfyllde QC-kriterierna

31 januari 2012

Första postat (Uppskatta)

2 februari 2012

Uppdateringar av studier

Senaste uppdatering publicerad (Uppskatta)

2 juni 2015

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

1 juni 2015

Senast verifierad

1 juni 2015

Mer information

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera